TXG - 10x Genomics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
60.65
-0.47 (-0.77%)
As of 12:16PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close61.12
Open61.71
Bid60.61 x 1300
Ask61.19 x 1200
Day's Range60.39 - 62.35
52 Week Range49.15 - 63.38
Volume118,833
Avg. Volume1,873,166
Market Cap5.783B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-7.27
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzinga

    The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 18) 10X Genomics Inc (NASDAQ: TXG ) (listed its shares ...

  • GlobeNewswire

    10x Genomics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

    PLEASANTON, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the closing of its initial public offering of 11,500,000 shares of its Class A common stock, which includes the exercise in full of the underwriters’ option to purchase 1,500,000 additional shares of its Class A common stock, at a public offering price of $39.00 per share. All of the shares were offered by 10x Genomics. Registration statements relating to these securities have been filed with the Securities and Exchange Commission, and became effective on September 11, 2019.

  • GlobeNewswire

    10x Genomics Announces Pricing of Initial Public Offering

    PLEASANTON, Calif., Sept. 12, 2019 -- 10x Genomics, Inc. (“10x Genomics”) today announced the pricing of its initial public offering of its Class A common stock at a price of.

  • Benzinga

    10X Genomics IPO: What You Need To Know

    10x Genomics plans to sell up to 9 million shares of Class A common stock at a price between $31 and $35 per share, according to documents filed with the U.S. Securities and Exchange Commission. 10x Genomics also plans to grant the underwriters an option for a period of 30 days to purchase up to 1.35 million additional shares at the IPO price.